The acquisition of the exclusive global license for the CDK2 inhibitor by BeiGene is likely to be viewed positively by investors as it strengthens the company's oncology pipeline. If the drug advances through clinical trials successfully, it could lead to significant revenue growth for BeiGene. However, the inherent risks of drug development and regulatory approval processes mean that the impact, while likely positive, is not guaranteed.